Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

November 30, 2024

Conditions
Cancer of CervixApoptosis
Interventions
DIAGNOSTIC_TEST

Immunohistochemistry

Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.

All Listed Sponsors
collaborator

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT06147960 - Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer | Biotech Hunter | Biotech Hunter